Substance P in long-lasting asthma: Immunoinflammatory pathways

Allergy and Clinical Immunology International

Volumn 18, Issue 6, 2006, Pages 242-248

  Todo Bom, Ana ^a   Pinto, A Mota ^b   Pereira, S Vale ^b   Alves, V ^b   Dourado, M ^b   Rosa, M Santos ^b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Asthma; CD26; DPPIV; Elderly; SOD; SP; TAS

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL PEPTIDASE IV; SUBSTANCE P; SUPEROXIDE DISMUTASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTHMA; BLOOD SAMPLING; BRONCHOSPASM; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; SKIN TEST;

EID: 33846997161     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: 10.1027/0838-1925.18.6.242     Document Type: Article

References (36)

1. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001; 33:555-576
2. National Heart, Lung and Blood Institute. New NHLBI guidelines for the diagnosis and management of asthma. Lippincott Health Promot Lett 1997; 2:8-9
3. Kupczyk M, Kuprys I, Gorski P, Kuna P. Long-term deterioration of lung function in asthmatic outpatients. Respiration 2004; 71:233-240
4. Braman S, Kaemmerlen J, Davis S. Asthma in the Elderly. Am Rev Respir Dis 1991; 143:336-340
5. Chanez P, Springall D, Vignola AM, Moradoghi-Hattvani A, Polak JM, Godard P, Bousquet J. Bronchial Mucosal Immunoreactivity of Sensory Neuropeptides in Severe Airway Diseases. Am J Respir Crit Care Med 1998; 158:985-990
6. Vignola AM, Scichilone N, Bousquet J, Bonsignore G, Bellia V. Aging and asthma: Pathophysiological mechanisms. Allergy 2003, 58:165-175
7. Van der Kleij HPM, Kraneveld AD, Redegeld FAM, Gerard NP, Morteau O, Nijkamp FP. The tachykinin NK1 receptor is crucial for the development of non-atopic airway inflammation and hyperresponsiveness. Eur J Pharmacol 2003; 476:249-255
8. Khodr B, Khalil Z. Modulation of inflammation by reactive oxygen species: Implications for aging and tissue repair. Free Radic Biol Med 2001; 30:1-8
9. Black PH. Stress and the inflammatory response: A review of neurogenic inflammation. Brain Behav Immun 2002; 16:622-653
10. Springer J, Groneberg DA, Pregla R, Fischer A. Inflammatory cells as source of tachykinin-induced mucus secretion in chronic bronchitis. Regul Pept 2005; 124:195-201
11. Chu HW, Kraft M, Krause JE, Rex MD, Martin RJ. Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol 2000; 106:713-722
12. Springer J, Pleimes D, Scholz FR, Fischer A. Substance P mediates AP-1 induction in A549 cells via reactive oxygen species. Regul Pept 2005; 124:99-103
13. Henderson Jr WR, Chi EY, Teo JL, Nguyen C, Kahn M. A small molecule inhibitor of redox-regulated NF-kappa B and activatorprotein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 2002; 169:5294-5299
14. Todo Bom A, Proença T, Resende Oliveira C, Cardoso Oliveira L, Chieira C. O Sistema Antioxidante na Asma Brônquica: Condicionalismos do Processo de Envelhecimento. Rev Portug Imunoalergol 2003; 11,17-29
15. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25:1454-1470
16. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78β into a most efficient monocyte attractant and CCR1 agonist. Blood 2000; 96:1674-1680
17. Lacroix JS. Chronic rhinosinusitis and neuropeptides. Swiss Med Wkly 2003; 133:560-562
18. Lacroix JS, Buvelot JM, Polla BS, Lundberg JM. Improvement of symptoms of non allergic chronic rhinitis by local treatment with capsaicin. Clinical Exp Allergy 1991; 21:595-600
19. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999; 20:367-375
20. Gabrilovaca J, Abramic M, Uzarevic B, Andreisd A, Poljake L. Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor. Life Sciences 2003; 73:151-166
21. Marilia Dourado. DPPIV/CD26 em Fisiopatologia Humana. Coimbra: University of Coimbra. 2000 (unpublished dissertation)
22. Knudson R, Slavin R, Lebowitz M, Burrows B. The maximum expiratory flow volume curve: Normal standards, variability and effects of age. Am Rev Respir Dis 1976; 113:587-600
23. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 1968; 243:5753-5760
24. Flohe L, Otting F. Superoxide dismutase assays. Methods Enzymol 1984; 105:93-104
25. Scharpe S, De Meester I, Vanhoof G, Hendriks D, van Sande M, Van Camp K, Yaron A. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin Chem 1988; 34:2299-2301
26. DeSouza CA, Clevenger CM, Greiner JJ, Smith DT, Hoetzer GL, Shapiro LF, Stauffer BL. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans. J Physiol 2002; 542:255-262
27. Dennett NS, Barcia RN, McLeod JD. Age-associated decline in CD25 and CD28 expression correlate with an increased susceptibility to CD95 mediated apoptosis in T cells. Exp Gerontol 2002; 37:271-283
28. Grouzmann E, Monod M, Landis B, Wilk S, Brankch N, Nicoucar NB, Giger R, Malis D, Szalay-Quinodoz I, Cavadas C, Morel DR, Lacroix JS. Loss of dipeptidylpaptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 2002; 16:1132-1134
29. Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S, De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin Chem Lab Med 2001; 39:155-159
30. Joos GF, Pauwels RA. Pro-inflammatory effects of substance P: New perspectives for the treatment of airway diseases? Trends Pharmacol Sci 2000; 21:131-133
31. Renwick DS, Connally MJ. Persistence of atopic effects on airway calibre and bronchial responsiveness in older adults. Age Ageing 1997; 26:435-440
32. Huss K, Naumann PL, Mason PJ, Nanda JP, Huss RW, Smith CM, Hamilton RG. Asthma severity, atopic status, allergen exposure, and quality of life in elderly persons. Ann Allergy Asthma Immunol 2001; 86:524-530
33. Kelly F, Tetley T. Nitrogen dioxide depletes uric acid and ascorbic acid but not glutathion from lung lining fluid. Biochem J 1997; 325:95-99
34. Smith L, Shamsuddin M, Sporn P, Denenberg M, Anderson J. Reduced superoxide dismutase in lung cells of patients with asthma. Free Radic Biol Med 1997; 95:1301-1307
35. Comhair S, Bhatena P, Dweik R, Kavuru M, Erurum S. Rapid loss of superoxide dismutase activity during antigen induced asthmatic response. Lancet 2000; 355:624
36. Saleh D, Ernest P, Lim S, Barnes P, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients with induction of nitric oxide synthetase: Effect of inhaled glucocorticoid. FASEB J 1998; 12:929-937